Technical Analysis for AQST - Aquestive Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 4.16 | -0.48% | -0.02 |
Earnings due: May 3
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Historical AQST trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Stochastic Buy Signal | Bullish | -0.48% | |
Spinning Top | Other | -0.48% | |
Wide Bands | Range Expansion | -0.48% | |
Oversold Stochastic | Weakness | -0.48% | |
Outside Day | Range Expansion | -2.35% | |
Wide Bands | Range Expansion | -2.35% | |
Oversold Stochastic | Weakness | -2.35% | |
Wide Bands | Range Expansion | 6.12% | |
Down 3 Days in a Row | Weakness | 6.12% | |
Down 4 Days in a Row | Weakness | 6.12% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
10 DMA Resistance | 12 minutes ago |
Rose Above 10 DMA | 30 minutes ago |
Down 1% | 30 minutes ago |
Up 1% | 30 minutes ago |
60 Minute Opening Range Breakdown | about 20 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/03/2021
Aquestive Therapeutics, Inc. Description
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Diseases Drugs Opioid Psychoactive Drugs Epilepsy Amyotrophic Lateral Sclerosis Chloroarenes Opioids Seizure Xone Seizures Gabaa Receptor Positive Allosteric Modulators Lactams Parkinson’s Disease Neuroendocrine Tumor Neuroendocrine Tumors Buprenorphine/Naloxone Riluzole
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 9.465 |
52 Week Low | 3.67 |
Average Volume | 904,873 |
200-Day Moving Average | 5.88 |
50-Day Moving Average | 4.93 |
20-Day Moving Average | 4.51 |
10-Day Moving Average | 4.28 |
Average True Range | 0.35 |
ADX | 16.38 |
+DI | 17.94 |
-DI | 24.20 |
Chandelier Exit (Long, 3 ATRs ) | 4.37 |
Chandelier Exit (Short, 3 ATRs ) | 4.92 |
Upper Bollinger Band | 5.25 |
Lower Bollinger Band | 3.78 |
Percent B (%b) | 0.27 |
BandWidth | 32.52 |
MACD Line | -0.23 |
MACD Signal Line | -0.20 |
MACD Histogram | -0.031 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.57 | ||||
Resistance 3 (R3) | 4.58 | 4.47 | 4.51 | ||
Resistance 2 (R2) | 4.47 | 4.37 | 4.46 | 4.48 | |
Resistance 1 (R1) | 4.32 | 4.31 | 4.27 | 4.31 | 4.46 |
Pivot Point | 4.21 | 4.21 | 4.18 | 4.20 | 4.21 |
Support 1 (S1) | 4.06 | 4.11 | 4.01 | 4.05 | 3.90 |
Support 2 (S2) | 3.95 | 4.05 | 3.94 | 3.88 | |
Support 3 (S3) | 3.80 | 3.95 | 3.86 | ||
Support 4 (S4) | 3.79 |